Bevacizumab biosimilar - BIOCND

Drug Profile

Bevacizumab biosimilar - BIOCND

Alternative Names: BCD 500

Latest Information Update: 26 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BIOCND
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Cancer

Most Recent Events

  • 26 Jul 2017 Phase-III clinical trials in Cancer in South Korea (Parenteral) (BIOCND pipeline, July 2017)
  • 16 Dec 2016 Preclinical trials in Cancer in South Korea (Parenteral), before December 2016
  • 16 Dec 2016 BIOCND files an IND application in South Korea for Cancer, before December 2016 (BIOCND pipeline, December 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top